Mosses in biotechnology
Key Findings
- Sphagnum species useful for environmental approaches and biomonitoring
- CO2-neutral 'farming' on rewetted bogs (paludiculture) combats climate change
- Moss extracts have diverse industrial and pharmaceutical applications
- Moss lifestyle genes for biotic and abiotic stress resistance relevant to crop improvement
- Physcomitrella patens genome fully sequenced — enables biotechnological engineering
Review published in Current Opinion in Biotechnology (2020) by Decker and Reski — two of the leading researchers in moss biology and biotechnology — examining the full range of biotechnological applications of mosses, with sphagnum prominently featured. Relevant to this knowledge graph primarily for the paludiculture and sustainability angle.
The Paludiculture Concept
The most significant finding for cosmetic peat: sphagnum moss can be farmed on rewetted peatlands in a CO2-neutral practice called paludiculture. Rather than draining and extracting ancient peat (which releases stored carbon), paludiculture grows new sphagnum on flooded land, harvests the surface biomass, and allows the bog to accumulate new peat underneath.
This matters for the cosmetic industry’s sustainability narrative. If sphagnum biomass for cosmetic use can be sourced from cultivated paludiculture operations rather than excavated from ancient deposits, the ecological equation changes entirely — from carbon-releasing extraction to carbon-neutral farming. Several Northern European projects (Germany, Estonia, Finland) are developing paludiculture as a commercial model.
Moss Metabolites and Pharmaceutical Applications
Sphagnum and other moss species produce a range of secondary metabolites under stress conditions: phenolic acids, terpenoids, and stress-response proteins. Decker and Reski note the pharmaceutical applications of moss extracts and the emerging genome-enabled biotechnology for engineering moss for specific metabolite production. For peat cosmetics, this research context establishes that sphagnum’s bioactive compounds are not incidental — they are evolved stress-response metabolites with specific biological functions.
Grade Note
Evidence grade C reflects that this is biology and biotechnology research — relevant context for mechanism and sustainability claims, not clinical evidence for therapeutic efficacy.